Drug Shortage Active
RIFADIN is currently in shortage. Reason: Available. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
Drug data last refreshed 16h ago · AI intelligence enriched 2mo ago
RIFADIN (rifampin) is a rifamycin-class antibacterial small molecule administered by injection, approved in 1989. It is used to treat serious bacterial infections, particularly tuberculosis and other mycobacterial diseases. Rifampin works by inhibiting bacterial RNA polymerase, disrupting transcription in susceptible organisms.
As a mature product approaching loss of exclusivity with moderate competitive pressure (30% rating), brand team size and commercial investment are likely modest.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on RIFADIN at this lifecycle stage offers experience in mature product management, supply chain optimization, and competitive positioning in antibacterials. This is not an ideal role for early-career growth; better suited for professionals experienced in LOE transition or consolidation strategies.
Worked on RIFADIN at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.